LivaNova (NASDAQ:LIVN) Sets New 1-Year Low - Here's Why

Shares of LivaNova PLC (NASDAQ:LIVN - Get Free Report) reached a new 52-week low on Thursday . The company traded as low as $40.03 and last traded at $40.02, with a volume of 70886 shares changing hands. The stock had previously closed at $40.87.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. StockNews.com lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 26th. Needham & Company LLC cut their target price on shares of LivaNova from $75.00 to $64.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group cut their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Barclays cut their target price on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a report on Friday. Finally, Stifel Nicolaus cut their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, LivaNova has an average rating of "Moderate Buy" and a consensus target price of $61.17.

Remove Ads

LivaNova Price Performance

The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm's 50 day simple moving average is $46.61 and its 200 day simple moving average is $49.30. The company has a market capitalization of $2.01 billion, a PE ratio of 88.14 and a beta of 1.10.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.27% of the company's stock.

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its position in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after purchasing an additional 219 shares during the last quarter. Sterling Capital Management LLC raised its holdings in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after acquiring an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division raised its holdings in shares of LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after acquiring an additional 720 shares in the last quarter. Captrust Financial Advisors bought a new stake in shares of LivaNova in the third quarter valued at about $217,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of LivaNova in the third quarter valued at about $219,000. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.